№ files_lp_4_process_3_113792
File format: docx
Character count: 23734
File size: 122 KB
Year:
2019–2024
Region:
International
Topic:
Oncology / Hepatocellular Carcinoma
Document Type:
Meta-analysis
Institution:
Multiple clinical research centers
Authors:
Various (from included RCTs)
Target Audience:
Medical researchers, oncologists, clinicians
Study Design:
Randomized controlled trials, Phase II and III
Interventions:
Nivolumab, Pembrolizumab, Atezolizumab, Sintilimab
Comparators:
Placebo, standard care, active surveillance
Outcomes Measured:
Overall survival (OS), Recurrence-free survival (RFS), adverse events (AEs)
Sample Size:
Data pooled from 10 studies
Statistical Methods:
DerSimonian-Laird random-effects model, hazard ratios (HRs), risk ratios (RRs)
Adverse Events Reported:
Fatigue, hypertension, elevated liver enzymes (grade 3+)
Publication Type:
Peer-reviewed articles
Description:
Systematic review and meta-analysis of clinical trials assessing survival outcomes and safety of adjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma after curative treatment.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / city:
Australia
Topic:
Oncology / Pharmaceutical
Document Type:
Submission
Agency:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
AstraZeneca Pty Ltd
Target Audience:
Medical professionals, regulatory authorities
Validity Period:
2021-2026
Approval Date:
20 April 2021
Modification Date:
Not specified
Year:
2023
Region / city:
Australia
Topic:
Vaccination, Immunocompromised individuals, Herpes Zoster
Document type:
Government recommendation
Organization:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
PBAC
Target audience:
Healthcare professionals, Immunocompromised individuals
Period of validity:
From November 1, 2023
Approval date:
November 1, 2023
Modification date:
September 2023
Year:
2019
Region / city:
Australia
Theme:
Oncology, Chemotherapy
Document type:
Resubmission for PBS listing
Organ / institution:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Bristol-Myers Squibb Australia Pty Ltd
Target audience:
Medical professionals, PBAC members
Validity period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
2019
Region / city:
Australia
Topic:
Adjuvant melanoma treatment
Document type:
Public Summary Document
Organization / institution:
PBAC
Author:
PBAC
Target audience:
Healthcare professionals
Period of validity:
Not specified
Approval date:
July 2019
Date of changes:
July 2019
Year:
2024
Region / City:
Guangzhou, Guangdong Province, China
Topic:
Hepatocellular carcinoma, postoperative radiation therapy
Document Type:
Research article
Organization / Institution:
The Third Affiliated Hospital of Sun Yat-sen University, Qilu Hospital, Shandong University, The First Affiliated Hospital, Guangzhou Medical University
Authors:
Gao-Yuan Yang, Zhi-Wei He, Yong-Chang Tang, Feng Yuan, Ming-Bo Cao, Yu-Peng Ren, Yu-Xuan Li, Xiao-Rui Su, Zhi-Cheng Yao, Mei-Hai Deng
Target Audience:
Medical researchers, clinicians specializing in oncology and hepatobiliary surgery
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Revision:
December 9, 2023
Date of Acceptance:
January 9, 2024
Funding:
The Science and Technology Plan Project of Guangzhou, National Natural Science Foundation Cultivation Project of The Third Affiliated Hospital of Sun Yat-sen University, Natural Science Foundation of Guangdong Province, CSCO-Roche Joint Cancer Research Fund
Year:
2015
Region / City:
Southeastern/Southwest United States
Field:
Medicine, Oncology
Document Type:
Abstract
Organization:
Texas Tech University Health Sciences Center, University of Pennsylvania
Author:
Paul Trippier, Kshitij Verma, Tianzhu Zang, Trevor M. Penning
Target Audience:
Researchers, Medical Professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Last Update:
Not specified
Year:
2012
Region / City:
Europe / Vienna
Theme:
Lung Cancer, Oncology
Document Type:
Survey
Organization / Institution:
European Society for Medical Oncology (ESMO)
Author:
Dr. Raffaele Califano
Target Audience:
Medical Oncologists, Radiation Oncologists
Period of Action:
Deadline end of February 2012
Approval Date:
N/A
Date of Changes:
N/A
Year:
2021
Institutes:
Walter and Eliza Hall Institute of Medical Research; Peter MacCallum Cancer Centre; University of Melbourne
Authors:
Yat Hang To, Peter Gibbs, Jeanne Tie, Maarten IJzerman, Koen Degeling
Type of document:
Systematic review supplementary material
Subjects:
Colorectal cancer, adjuvant therapy, health economics
Search period:
8th July 2021 – 10th December 2021
Databases searched:
Medline, EMBASE, Health Technology Assessment Database, National Health Service Health Economic Evaluation Database
Language:
English
Corresponding author:
Yat Hang To
ORCID ID:
0000-0002-1497-1700
Email:
[email protected]
Coverage:
Stage II and III colorectal cancer
Year:
2026
Region / city:
Canadian Ski Marathon
Theme:
Checkpoint operations, volunteer duties, and event coordination
Document type:
Manual
Organization / institution:
Canadian Ski Marathon
Author:
CSM Event Director, CSM Admin-2
Target audience:
Event leaders, checkpoint/task leaders, volunteers
Period of validity:
February 6-8, 2026
Approval date:
N/A
Modification date:
N/A
Year:
2019
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme, PD-(L)1 inhibitors, non-small cell lung cancer (NSCLC)
Document type:
Meeting minutes
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Professor Andrew Wilson (PBAC Chair)
Target audience:
Stakeholders in the healthcare and pharmaceutical industry
Period of validity:
2019 and onwards
Date of approval:
February 2019
Date of amendments:
Not specified
Year:
2023
Region / City:
Wuhan, China
Topic:
Immunology, Cancer Research, Gene Expression, Immunotherapy
Document Type:
Research Article
Institution:
Wuhan University of Science & Technology, Huazhong University of Science and Technology, Anhui Normal University
Authors:
Fei-Fei Hu, Chun-Jie Liu, Lan-Lan Liu, Qiong Zhang, An-Yuan Guo
Target Audience:
Researchers, Healthcare Professionals, Academics in Immunology and Oncology
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Year:
2026
Region / City:
N/A
Theme:
American Sign Language Assessment
Document Type:
Examination
Institution:
N/A
Author:
N/A
Target Audience:
Students of American Sign Language
Validity Period:
N/A
Approval Date:
June 22, 2026
Modification Date:
N/A
Date:
June 24, 2025
Region / City:
Hemet, California, United States
Topic:
Road safety and impaired driving enforcement
Document Type:
Press release / public safety announcement
Organization:
Hemet Police Department
Prepared by:
Sergeant M. Chavez
Contact Person:
Sergeant Matt Chavez
Contact Phone:
(951) 765-2400
Contact Email:
[email protected]
Media Contact:
Public Information Social Media Officer Judith Gibson
Media Contact Email:
[email protected]
Event Date:
July 11, 2025
Event Time:
8:00 pm – 2:00 am
Event Type:
DUI and Driver’s License Checkpoint
Location:
Undisclosed location within the City of Hemet
Funding Source:
California Office of Traffic Safety grant through the National Highway Traffic Safety Administration
Target Audience:
Drivers and residents of the City of Hemet
Subject Details:
Enforcement of laws related to driving under the influence of alcohol, drugs, prescription medication, and marijuana
Year:
2018
Region:
Australia
Subject:
PD-1 and PD-L1 checkpoint inhibitor immunotherapies
Document Type:
Submission Template
Organization:
Pharmaceutical Benefits Advisory Committee (PBAC)
Intended Audience:
Patients, healthcare providers, researchers, pharmaceutical industry, government bodies
Submission Deadline:
29 June 2018
Contact Information Required:
Yes
Confidentiality Note:
Commercial-in-confidence or personal information to be redacted before publication
Format:
Electronic submission in Microsoft Word or text-based format
Questions Covered:
Advantages, disadvantages, unmet clinical need, evidence requirements, cost-effectiveness, subsidy pricing, biomarker considerations, extrapolation across medicines and cancer types, rare cancers, follow-up actions, clinical trials, international models
Year:
2021
Region / city:
Not specified
Topic:
Resource multiplexing between child and parent links of IAB node
Document type:
Contribution
Organization:
3GPP TSG RAN WG1
Author:
Moderator (AT&T)
Target audience:
3GPP members, stakeholders in telecommunications standards
Period of validity:
January 25th – February 5th, 2021
Approval date:
Not specified
Amendment date:
Not specified
Summary:
This document provides a summary of various proposals for improving resource multiplexing between the child and parent links of an IAB node, particularly focused on simultaneous operations, frequency domain multiplexing, and operational resource configurations.
Year:
2021
Organization:
3GPP TSG RAN WG1
Document type:
Technical contribution
Source:
Moderator (AT&T)
Title:
Summary of [104-e-NR-eIAB-01] – 1st Checkpoint
Agenda item:
8.10.1
Scope:
Enhancements to resource multiplexing between child and parent links of an IAB node
Contributors:
Huawei, Vivo, Intel, CEWiT, IITM, IITH, Tejas Networks, Reliance Jio
Target audience:
RAN working group members
Checkpoint dates:
Jan 27, Feb 5, Feb 13
Topics covered:
Simultaneous operation of access and backhaul links, dual-connectivity, TDD configurations, resource allocation strategies
Year:
2014
Software Version:
vCO 5.5.2, vRO HTTP REST Plugin 1.0.7
Region:
Global
Document Type:
Installation and Configuration Guide
Author:
VMware / CheckPoint
Target Audience:
System administrators, IT engineers
Required Environment:
vCenter 5.5.0, Windows client for vCO, CheckPoint Management Server
Procedures Included:
OVF deployment, password setup, network configuration, SSL certificate import, SSO authentication, plugin installation, workflow execution
Troubleshooting Notes:
Password issues, SSL key errors, time synchronization
Workflow Examples:
Add Host, Add Host to Group, Add Access Rule, Install Policy